Aspire Biopharma Q2 FY26 net loss narrows to $1.27 million; revenue rises to $63,104

Reuters2026/08/13 20:40

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Aspire Biopharma posted Q2 net loss of USD 1.27 million, narrowing from USD 1.98 million a year earlier.
Revenue was USD 63,104, versus no revenue a year earlier; gross margin was negative USD 30,086 on USD 42,372 inventory write-off.
Operating loss widened to USD 2.68 million from USD 799,890, as sales and marketing climbed to USD 1.22 million from USD 51,311.
Six-month net loss narrowed to USD 4.49 million from USD 17.92 million; operating loss improved to USD 4.32 million from USD 16.36 million.
Completed acquisition of Dura Drive Control Systems on Aug. 10, 2026, targeting increased revenue, earnings, and cash flow from automotive control systems.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-037819), on August 13, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Aspire Biopharma Q2 FY26 net loss narrows to $1.27 million; revenue rises to $63,104

You may also like

Crypto prices